{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-070582","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2023-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.022182+00:00","generated_at":"2026-06-07T11:57:36.564659+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CHMP positive opinion for CASGEVY conditional EU approval in sickle cell and beta thalassemia","bullets":["EMA's CHMP adopted positive opinion for conditional approval of CASGEVY (exagamglogene autotemcel) for severe sickle cell disease and transfusion-dependent beta thalassemia.","CASGEVY is a CRISPR/Cas9 gene-edited therapy jointly developed by CRISPR Therapeutics and Vertex Pharmaceuticals.","European Commission decision expected in February 2024; conditional marketing authorizations are valid one year, renewable annually."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-070582","json":"https://secwatch.observer/filing/0000950170-23-070582.json","markdown":"https://secwatch.observer/filing/0000950170-23-070582.md","text":"https://secwatch.observer/filing/0000950170-23-070582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023070582/0000950170-23-070582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023070582/crsp-20231215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:57:36.564659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}